Form 6-K BioNTech SE For: Aug 20

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/28/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK
6. S
7. GAP
8. DG
9. ULTA
10. ADSK

August 20, 2026 7:37 AM EDT


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF AUGUST 2026

COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐



DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On August 20, 2026, BioNTech SE announced that it will present new clinical data from its diversified development program in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer (“WCLC”) in Seoul, Republic of Korea, from September 12-15, 2026. The press release is attached as Exhibit 99.1.


SIGNATURE
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE
By:
/s/ Ramon Zapata-Gomez
By:
/s/ Dr. Sierk Poetting
Name: Ramon Zapata-Gomez
Name: Dr. Sierk Poetting
Title: Chief Financial Officer
Title: Chief Operating Officer
Date: August 20, 2026


EXHIBIT INDEX




ATTACHMENTS / EXHIBITS

EX-99.1


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings